Patent SG-11201903236S-A (SG)
Title: Lasofoxifene treatment of er+ breast cancer
Inventor: ANDREANO KAITLYN
IPC: A61K31/00
Filed: 2017-10-10
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111 IOU 0 11101 HOE 3E1 0 011101111111111111110 MO 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/093484 Al 24 May 2018 (24.05.2018) W I PO I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) Applicant: DUKE UNIVERSITY [US/US]; 2812 Erwin (72) Inventors: ANDREANO, Kaitlyn; c/o Duke University, International Patent Classification: NC 27705 (US). GAILLARD, Stephanie, L.; c/o Duke A61K 31/00 (2006.01) A61P 35/00 (2006.01) University, 2812 Erwin Road, Suite 306, Box 90083, A61K 31/40 (2006.01) A61K 45/06 (2006.01) Durham, NC 27705 (US). A61P 35/04 (2006.01) (74) Agent: SUN, Danqiong et al.; Fenwick & West LLP, Sili- International Application Number: con Valley Center, 801 California Street, Mountain View, PCT/US2017/055970 CA 94041 (US). International Filing Date: (81) Designated States (unless otherwise indicated, for every 10 October 2017 (10.10.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/406,859 11 October 2016 (11.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/457,759 10 February 2017 (10.02.2017) US May 2017 (05.05.2017) US 62/502,299 05 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Road, Suite 306, Box 90083, Durham, NC 27705 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, 2812 Erwin Road, Suite 306, Box 90083, Durham, NC GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 27705 (US). CHANG, Ching-yi; c/o Duke University, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 2812 Erwin Road, Suite 306, Box 90083, Durham, NC TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 27705 (US). MCDONNELL, Donald, P.; c/o Duke Uni- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, versity, 2812 Erwin Road, Suite 306, Box 90083, Durham, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, _ = = Title: LASOFOXIFENE TREATMENT 1.5 m _ ce co N ct — E o z 0.0 : The disclosure provides lasofoxifene, a pharmaceutically acceptable Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine (54) M FIG. ei Estrogen _1 1.0 OF ER+ BREAST CANCER Lasofoxifene women with an effective amount includes the detection of the resistant ER cancers. + = = = = = —0— WT —o— Y537N Y537S - V - Y537C —0—D538G = — = %.- 0.5 • • y = _ = — = — 1-1 iv o r © p o p (57) C of • v 0 -12 -10 -8 Log [M] 2B methods for treating estrogen receptor positive (ER ) cancer in + salt thereof, or a prodrug thereof. The disclosure also o [Continued on next page] WO 2018/093484 Al 111111111111110111011111111111011111010111110111111100111111111111111111011110111111 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt amendments (Rule 48.2(h)) of — with sequence listing part of description (Rule 5.2(a))